{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:25:26Z","timestamp":1774430726911,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jfma.2026.01.064","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:48:34Z","timestamp":1769946514000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Physicians, case managers, and HCV patients recommend a simplified strategy for baseline testing and minimal monitoring for treatment of hepatitis C virus infection with DAA therapies"],"prefix":"10.1016","author":[{"given":"Chun-Jen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Jung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6298-8507","authenticated-orcid":false,"given":"Kyung min","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jfma.2026.01.064_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03006-3","article-title":"Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.064_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40121-021-00576-7","article-title":"Sofosbuvir\/velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan","volume":"11","author":"Cheng","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.064_bib4","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/liv.14849","article-title":"Factors associated with treatment failure of direct\u2010acting antivirals for chronic hepatitis C: a real\u2010world nationwide hepatitis C virus registry programme in Taiwan","volume":"41","author":"Chen","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2026.01.064_bib5","article-title":"Welfare","author":"Health","year":"2019","journal-title":"Taiwan hepatitis C policy guidelines 2018\u20102025"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.064_bib6","first-page":"1","volume":"40","author":"Wu","year":"2021","journal-title":"Eliminating hepatitis C in Taiwan by 2025: strategies and progress Taiwan Journal of Public Health"},{"issue":"4","key":"10.1016\/j.jfma.2026.01.064_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.064_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2019.10.010","article-title":"Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial","volume":"72","author":"Dore","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.064_bib9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.23802","article-title":"Expanding access to hepatitis C virus treatment\u2014Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care","volume":"52","author":"Arora","year":"2010","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jfma.2026.01.064_bib10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/jvh.13746","article-title":"HCV hotline facilitates Hepatitis C elimination during the COVID\u201019 pandemic","volume":"29","author":"Hartl","year":"2022","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.jfma.2026.01.064_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.nurpra.2020.09.013","article-title":"Telehealth benefits and barriers","volume":"17","author":"Gajarawala","year":"2021","journal-title":"J Nurse Pract"},{"issue":"7","key":"10.1016\/j.jfma.2026.01.064_bib12","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.3390\/ijerph18073694","article-title":"Telemedicine chronic viral hepatitis C treatment during the lockdown period in Romania: a pilot study","volume":"18","author":"Doica","year":"2021","journal-title":"Int J Environ Res Publ Health"},{"issue":"15","key":"10.1016\/j.jfma.2026.01.064_bib13","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.3390\/jcm12155128","article-title":"Telemedicine in patients affected by chronic liver disease: a scoping review of clinical outcomes and the devices evaluated","volume":"12","author":"Capuano","year":"2023","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.jfma.2026.01.064_bib14","doi-asserted-by":"crossref","DOI":"10.2196\/20874","article-title":"Use of telemedicine for chronic liver disease at a single care center during the COVID-19 pandemic: prospective observational study","volume":"22","author":"Guarino","year":"2020","journal-title":"J Med Internet Res"},{"issue":"8","key":"10.1016\/j.jfma.2026.01.064_bib15","doi-asserted-by":"crossref","first-page":"p1201","DOI":"10.1016\/j.jiph.2023.05.019","article-title":"A new collaborative care approach toward hepatitis C elimination in marginalized populations","volume":"16","author":"Su","year":"2023","journal-title":"J Infect Public Health"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626000999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626000999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:59:53Z","timestamp":1770350393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664626000999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":14,"alternative-id":["S0929664626000999"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.01.064","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physicians, case managers, and HCV patients recommend a simplified strategy for baseline testing and minimal monitoring for treatment of hepatitis C virus infection with DAA therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.01.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}